MiR−33 as a novel diagnostic biomarker for distinguishing cholesterol from adenomatous polyps: a case-control study

Hereditas, Journal Year: 2025, Volume and Issue: 162(1)

Published: March 14, 2025

Abstract Cholecystectomy is often excessively utilized in the management of gallbladder polyps. It crucial to effectively differentiate between adenomatous and cholesterol polyps reduce unnecessary cholecystectomies. This study aimed investigate potential miR−33 as a novel diagnostic biomarker for distinguishing from Gallbladder specimens were retrospectively collected polyp patients who underwent laparoscopic cholecystectomy at Second Department General Surgery, Dongzhimen Hospital, Beijing University Traditional Chinese Medicine, June 2021 December 2021. Pathological analysis categorized into two groups: group ( n = 13) 12). The expression levels miR−33a miR−33b both groups assessed using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). MiR-33a level miR-33a/miR-33b ratio significantly lower than p < 0.05). Spearman correlation showed strong positive miR-33a miR-33b r 0.956, 0.001). Stepwise logistic regression revealed that decreased elevated are independent risk factors A predictive model was constructed, with model’s AUC diagnosing being 0.885 (95% CI: 0.753−1.000, 0.001), exhibiting notable specificity 84.62% sensitivity 83.33% cut-off 0.424. MiR−33 could serve facilitate diagnosis treatment clinicians.

Language: Английский

Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management

Frontiers in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 20, 2025

RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted lot of research on the application technology in treatment CVDs. Despite hurdles off-target effects immune responses, clinical trial outcomes encouraging. This review synthesizes current progress CVDs, examining their mechanisms, advantages, challenges delivery safety. We highlight potential personalized medicine, combination artificial intelligence (AI) bioinformatics advancing therapeutics. The future CVDs is poised significant impact, necessitating continued interdisciplinary collaboration to optimize these treatments ensure patient safety efficacy.

Language: Английский